BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23911703)

  • 21. Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes.
    Rampazzo E; Bonaldi L; Trentin L; Visco C; Keppel S; Giunco S; Frezzato F; Facco M; Novella E; Giaretta I; Del Bianco P; Semenzato G; De Rossi A
    Haematologica; 2012 Jan; 97(1):56-63. PubMed ID: 21933855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of clinical staging in chronic lymphocytic leukemia- population-based study.
    Apelgren P; Hasselblom S; Werlenius O; Nilsson-Ehle H; Andersson PO;
    Leuk Lymphoma; 2006 Dec; 47(12):2505-16. PubMed ID: 17169795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
    Wierda WG; O'Brien S; Wang X; Faderl S; Ferrajoli A; Do KA; Cortes J; Thomas D; Garcia-Manero G; Koller C; Beran M; Giles F; Ravandi F; Lerner S; Kantarjian H; Keating M
    Blood; 2007 Jun; 109(11):4679-85. PubMed ID: 17299097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.
    Lucas DM; Ruppert AS; Lozanski G; Dewald GW; Lozanski A; Claus R; Plass C; Flinn IW; Neuberg DS; Paietta EM; Bennett JM; Jelinek DF; Gribben JG; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS; Byrd JC; Grever MR
    Leuk Lymphoma; 2015; 56(11):3031-7. PubMed ID: 25721902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia.
    Gattei V; Bulian P; Del Principe MI; Zucchetto A; Maurillo L; Buccisano F; Bomben R; Dal-Bo M; Luciano F; Rossi FM; Degan M; Amadori S; Del Poeta G
    Blood; 2008 Jan; 111(2):865-73. PubMed ID: 17959854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia.
    Gladstone DE; Swinnen L; Kasamon Y; Blackford A; Gocke CD; Griffin CA; Meade JB; Jones RJ
    Leuk Lymphoma; 2011 Oct; 52(10):1873-81. PubMed ID: 21851216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
    Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
    Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of age and treatment institution type on outcomes of patients treated for chronic lymphocytic leukemia in British Columbia, Canada.
    Huang SJ; Gerrie AS; Young S; Tucker T; Bruyère H; Hrynchak M; Galbraith P; Al Tourah AJ; Dueck G; Noble MC; Ramadan KM; Tsang P; Hardy E; Sehn LH; Toze CL
    Leuk Res; 2021 Apr; 103():106538. PubMed ID: 33647819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.
    Martínez-Trillos A; Pinyol M; Delgado J; Aymerich M; Rozman M; Baumann T; González-Díaz M; Hernández JM; Alcoceba M; Muntañola A; Terol MJ; Navarro B; Giné E; Jares P; Beà S; Navarro A; Colomer D; Nadeu F; Colado E; Payer AR; García-Cerecedo T; Puente XS; López-Otin C; Campo E; López-Guillermo A; Villamor N
    Leuk Lymphoma; 2018 Oct; 59(10):2318-2326. PubMed ID: 29115891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baseline Characteristics Predicting Very Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Patients With High Cytogenetic Risk Chronic Lymphocytic Leukemia - A Retrospective Analysis From the Chronic Malignancies Working Party of the EBMT.
    van Gelder M; Ziagkos D; de Wreede L; van Biezen A; Dreger P; Gramatzki M; Stelljes M; Andersen NS; Schaap N; Vitek A; Beelen D; Lindström V; Finke J; Passweg J; Eder M; Machaczka M; Delgado J; Krüger W; Raida L; Socié G; Jindra P; Afanasyev B; Wagner E; Chalandon Y; Henseler A; Schoenland S; Kröger N; Schetelig J;
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):667-675.e2. PubMed ID: 28694085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia.
    Gunnarsson R; Mansouri L; Isaksson A; Göransson H; Cahill N; Jansson M; Rasmussen M; Lundin J; Norin S; Buhl AM; Smedby KE; Hjalgrim H; Karlsson K; Jurlander J; Geisler C; Juliusson G; Rosenquist R
    Haematologica; 2011 Aug; 96(8):1161-9. PubMed ID: 21546498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era.
    Nabhan C; Raca G; Wang YL
    JAMA Oncol; 2015 Oct; 1(7):965-74. PubMed ID: 26181643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953-2012: a systematic analysis of population-based data.
    Lenartova A; Johannesen TB; Tjønnfjord GE
    Cancer Med; 2016 Dec; 5(12):3588-3595. PubMed ID: 27925456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostication of chronic lymphocytic leukemia in the era of new agents.
    Eichhorst B; Hallek M
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):149-155. PubMed ID: 27913474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.
    Weinberg JB; Volkheimer AD; Chen Y; Beasley BE; Jiang N; Lanasa MC; Friedman D; Vaccaro G; Rehder CW; Decastro CM; Rizzieri DA; Diehl LF; Gockerman JP; Moore JO; Goodman BK; Levesque MC
    Am J Hematol; 2007 Dec; 82(12):1063-70. PubMed ID: 17654680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abdominal computed tomography predicts progression in patients with Rai stage 0 chronic lymphocytic leukemia.
    Muntañola A; Bosch F; Arguis P; Arellano-Rodrigo E; Ayuso C; Giné E; Crespo M; Abrisqueta P; Moreno C; Cobo F; López-Guillermo A; Montserrat E
    J Clin Oncol; 2007 Apr; 25(12):1576-80. PubMed ID: 17353549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
    Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A;
    Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
    Herling CD; Coombes KR; Benner A; Bloehdorn J; Barron LL; Abrams ZB; Majewski T; Bondaruk JE; Bahlo J; Fischer K; Hallek M; Stilgenbauer S; Czerniak BA; Oakes CC; Ferrajoli A; Keating MJ; Abruzzo LV
    Lancet Oncol; 2019 Nov; 20(11):1576-1586. PubMed ID: 31582354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.
    Plesingerova H; Librova Z; Plevova K; Libra A; Tichy B; Skuhrova Francova H; Vrbacky F; Smolej L; Mayer J; Bryja V; Doubek M; Pospisilova S
    Leuk Lymphoma; 2017 Jan; 58(1):70-79. PubMed ID: 27185377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of
    Plešingerová H; Janovská P; Mishra A; Smyčková L; Poppová L; Libra A; Plevová K; Ovesná P; Radová L; Doubek M; Pavlová Š; Pospíšilová Š; Bryja V
    Haematologica; 2018 Feb; 103(2):313-324. PubMed ID: 29122990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.